219 related articles for article (PubMed ID: 27581465)
1. Gastric cancer: current and evolving treatment landscape.
Sun W; Yan L
Chin J Cancer; 2016 Aug; 35(1):83. PubMed ID: 27581465
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy for patients with advanced gastric cancer.
Takahari D
Gastric Cancer; 2017 May; 20(3):395-406. PubMed ID: 28260227
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Therapies for Advanced Gastric Cancer.
Davidson M; Okines AF; Starling N
Clin Colorectal Cancer; 2015 Dec; 14(4):239-50. PubMed ID: 26524924
[TBL] [Abstract][Full Text] [Related]
4. The journey of personalizing gastric cancer treatment.
Yan L
Chin J Cancer; 2016 Aug; 35(1):84. PubMed ID: 27581614
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for advanced gastric cancer: future perspective in Japan.
Shitara K
Gastric Cancer; 2017 Mar; 20(Suppl 1):102-110. PubMed ID: 27699493
[TBL] [Abstract][Full Text] [Related]
6. Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article.
Siebenhüner AR; De Dosso S; Helbling D; Astaras C; Szturz P; Moosmann P; Pederiva S; Winder T; Von Burg P; Borner M
Oncol Res Treat; 2021; 44(9):485-494. PubMed ID: 34350899
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status.
Higuchi K; Tanabe S; Azuma M; Sasaki T; Ishido K; Koizumi W
Pathobiology; 2011; 78(6):334-42. PubMed ID: 22104205
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II clinical trials for gastric cancer.
Khushalani NI
Surg Oncol Clin N Am; 2012 Jan; 21(1):113-28. PubMed ID: 22098835
[TBL] [Abstract][Full Text] [Related]
9. [Novel pharmaceutical treatment approaches for gastric cancer].
Lordick F
Pathologe; 2017 Mar; 38(2):87-92. PubMed ID: 28220199
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy in the treatment of gastric cancer].
Ahn MJ
Korean J Gastroenterol; 2004 Feb; 43(2):75-81. PubMed ID: 14978363
[TBL] [Abstract][Full Text] [Related]
11. Advances of Molecular Targeted Therapy in Gastric Cancer.
Cetin B; Gumusay O; Cengiz M; Ozet A
J Gastrointest Cancer; 2016 Jun; 47(2):125-34. PubMed ID: 26875080
[TBL] [Abstract][Full Text] [Related]
12. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J
Ann Oncol; 2017 Jun; 28(6):1207-1216. PubMed ID: 28327938
[TBL] [Abstract][Full Text] [Related]
13. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
14. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
Kim R; Tan A; Choi M; El-Rayes BF
Crit Rev Oncol Hematol; 2013 Nov; 88(2):416-26. PubMed ID: 23764501
[TBL] [Abstract][Full Text] [Related]
15. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
16. [Molecular targeting agents for advanced or recurrent gastric cancer patients].
Fuse N
Nihon Rinsho; 2012 Oct; 70(10):1819-26. PubMed ID: 23198568
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
Al-Batran SE; Werner D
Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapies in advanced gastric cancer.
Janjigian YY; Shah MA
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
